Merck/Schering-Plough Press Releases
Press Releases
Information About the SEAS Study
Information About the ENHANCE Trial
Frequently Asked Questions
Home
About Us
Patient Assistance Program
Responsibility and Compliance
Company News
Press Releases
Information About the SEAS Study
Information About the ENHANCE Trial
Frequently Asked Questions
MERCK/Schering-Plough Pharmaceuticals

Information About the SEAS Study

Information From Merck / Schering-Plough

Letter to Health Care Professionals – 09/02/08 (for health care professionals only)
Letter to Health Care Professionals – 07/22/08 (for health care professionals only)
Pedersen Release – 07/21/08

Prescribing Information for VYTORIN® (ezetimibe/simvastatin)
Patient Product Information for VYTORIN

Additional Information

Follow-Up to the August 2008 Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as VYTORIN), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as ZETIA) - FDA Investigates a Report from the SEAS Trial
The New England Journal of Medicine Articles – 09/02/08
University of Oxford Clinical Trial Service Unit & Epidemiological Studies Unit Release – 09/02/08
(supersedes University of Oxford Clinical Trial Service Unit & Epidemiological Studies Unit Release – 07/21/08)
FDA Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as VYTORIN), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as ZETIA) – 08/21/08

Prescribing Information for VYTORIN
Patient Product Information for VYTORIN

Prescribing Information for ZETIA® (ezetimibe)
Patient Product Information for ZETIA